Perioperative body weight change is associated with in-hospital mortality in cardiac surgical patients with postoperative acute kidney injury

Chih-Chung Shiao1,2, Ya-Ting Huang3,4, Tai-Shuan Lai5, Tao-Min Huang5, Jian-Jhong Wang6, Chun-Te Huang7, Pei-Chen Wu8, Che-Hsiung Wu9,10, I-Jung Tsai11, Li-Jung Tseng12, Chih-Hsien Wang12*, Kwan-Dun Wu5, Vin-Cent Wu5, for the National Taiwan University Hospital Study Group on Acute Renal Failure (NSARF)¶

1 Division of Nephrology, Department of Internal Medicine, Saint Mary’s Hospital Luodong, Yilan, Taiwan, R.O.C., 2 Saint Mary’s Junior College of Medicine, Nursing and Management, Yilan, Taiwan, R.O.C., 3 Department of Nursing, Saint Mary’s Hospital Luodong, Yilan, Taiwan, R.O.C., 4 Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, R.O.C., 5 Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C., 6 Division of Nephrology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying, Taiwan, R.O.C., 7 Division of Internal & Critical Care Medicine, Department of Critical care Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C., 8 Division of Nephrology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan, R.O.C., 9 Division of Nephrology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, Taiwan, R.O.C., 10 School of Medicine, Tzu Chi University, Hualien, Taiwan, R.O.C., 11 Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan, R.O.C., 12 Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.

¶ Membership of the National Taiwan University Hospital Study Group on Acute Renal Failure (NSARF) is provided in the Acknowledgments.

* wchemail@gmail.com

Abstract

Background

Postoperative acute kidney injury (AKI) is common following cardiac surgery (CS). Body weight (BW) may be an amenable variable by representing the summation of the nutritional and the fluid status. However, the predictive role of perioperative BW changes in CS patients with severe postoperative AKI is never explored. This study aimed to evaluate this association.

Methods

This study was conducted using a prospectively collected multicenter cohort, NSARF (National Taiwan University Hospital Study Group on Acute Renal Failure) database. The adult CS patients with postoperative AKI requiring renal replacement therapy (RRT), who had clear initial consciousness, received CS within 14 days of hospitalization, and underwent RRT within seven days after CS in intensive care units from January 2001 to January 2014 were enrolled. With the endpoint of 30-day postoperative mortality, we evaluated the association between the clinical factors denoting fluid status and patients outcomes.
Results

A total of 188 patients (70 female, mean age 63.7 ± 15.2 years) were enrolled. Comparing with the survivors (n = 124), the non-survivors (n = 64) had a significantly higher perioperative BW change [3.6 ± 6.1% versus 0.1 ± 8.3%, p = 0.003] but not the postoperative and pre-RRT BW changes. By using multivariate Cox proportional hazards model, the independent indicators of 30-day postoperative mortality included perioperative BW change (p = 0.026) and packed red blood cells transfusion (p = 0.007), postoperative intra-aortic balloon pump (p = 0.001) and central venous pressure level (p = 0.005), as well as heart rate (p = 0.022), sequential organ failure assessment score (p < 0.001), logistic organ dysfunction score (p = 0.001), and blood total bilirubin level (p = 0.044) at RRT initiation. The generalized additive models further demonstrated, in a multivariate manner, that the mortality risk rose significantly during a perioperative BW change of 2% to 15%.

Conclusions

Perioperative BW change was independently associated with an increased risk for 30-day postoperative mortality in CS patients with RRT-requiring AKI.

Introduction

Acute kidney injury (AKI) is a common yet potentially serious complication after cardiac surgery (CS). Among the patients underwent CS, about 17–49% suffer from postoperative AKI, and 2–6% have severe AKI requiring renal replacement therapy (RRT). [1–3] The AKI has a dose-response relationship between its severity and the adverse effect on long-term survival of the patients. [4] The pathophysiology of postoperative AKI in CS patients is complex and multifactorial, which includes several factors such as exogenous and endogenous toxins, metabolic factors, ischemia-reperfusion injury, neurohormonal activation, embolization, hemodynamic alterations, along with inflammation and oxidative stress. These mechanisms likely interact with each other at different time points during the period from preoperative stage to postoperative stages of the CS. [5–7]

The postoperative prognoses after CS are varied with many factors such as patient characteristics, preexisting comorbidities, inflammatory activity, and duration of extracorporeal circulation. [8, 9] Besides, body weight (BW) or BW change is also an important but often overlooked indicator for patient outcomes in many clinical settings. [9, 10] It is accepted that an unintended BW loss of > 10% within six months is indicative of undernutrition and is associated with adverse patient outcomes. [11] In the patients undergoing CS, both preoperative unintended BW loss of ≥ 10% in the past 6 months and BMI ≤ 21.0 kg/m² were found as independent indicators for a prolonged hospital length of stay (LOS) in a prospective cohort study by van Venrooij et al. [9] While a BW loss > 5% during the follow-up with a median period of 6 months was found as a significant risk factor for death and cardiovascular death in patients post myocardial infarction in a randomized clinical trial conducted by Lopez-Jimenez et al. [12] On the contrary, a BW gain ≥ 2 pounds (0.91 kg) over 3 days was a significant indicator for heart function decompensation and worse outcomes in patients with heart failure with preserved ejection fraction. [13] It is straightforward that the fluid retention secondary to the heart failure is majorly accountable for the increased BW.

Physiologically, the patient during the perioperative stage is in a stressful situation with highly dynamic and catabolic status which on the one hand would precipitate BW loss via the...
depletion of glycogen and subcutaneous fat, as well as the wasting of the muscle. [14] But on the other hand, the response to the stress of the patients may cause the BW gain by fluid retention, which is through the secretion of antidiuretic hormone, renin, and aldosterone. [15] In the aspect of fluid retention, excessive fluid accumulation is not only demonstrated to link with the raised morbidities and mortality in patients with critical illness or AKI, and those undergoing major surgeries, [16, 17] but also shown to be associated with higher risk of subsequent AKI. [18]

Among the CS patient with severe postoperative AKI, the RRT-requiring AKI worsens the patient outcomes, [19] which draws the attention at least on the issues of fluid status and nutrition. By representing the summation of the nutritional situation and the fluid status, BW may be an amenable variable as an intervention target in clinical practice. [10] However, the role of perioperative BW change in predicting patient outcomes in CS patients with RRT-requiring AKI is never explored previously. Thus, we conducted the current study aiming to evaluate this association in this population.

Material and methods

Study design and participants

This study was conducted using a prospectively collected multicenter cohort, NSARF (National Taiwan University Hospital Study Group on Acute Renal Failure) database [20–22]. The adult patients (aged > 18 years) who received CS with postoperative AKI requiring RRT support in intensive care units (ICUs) from January 2001 to January 2014 were enrolled. To purify the patient characteristics and limit the potential confounding factors, the inclusion criteria comprised the following: with clear consciousness at initial hospitalization, receiving CS within 14 days after hospitalization, [23] and undergoing RRT within seven days after the surgeries. [24] The exclusion criteria included patients who were on chronic RRT or received acute RRT before the CS. The enrolled patients were categorized into two groups, survivors and non-survivors, based on the 30-day postoperative mortality. Then we evaluated the association between BW changes and patient survivals.

Ethics, consent, and permissions

The Institutional Review Board of National Taiwan University Hospital approved the study (No. 31 MD03) and waived the need for informed consent because of the absence of both breach of privacy and interference with clinical decisions. The data were analyzed anonymously as well.

Endpoint of current study

The endpoint of the current study is the 30-day postoperative mortality which was defined as patient mortality \( \leq 30 \) days after surgeries. [25] The censoring period was calculated from the calendar day of receiving CS to the mortality (in non-survivors) or the 31st postoperative day (in survivors).

Data collection

The baseline demographic data, comorbid diseases, Charlson Comorbidity Index (CCI), types of surgeries, etiology of AKI, modalities of RRT, and other remarkable information during the hospitalization were documented. This information included the amount of perioperative blood transfusion, diuretic therapy, as well as usage of intra-aortic balloon pump (IABP),
extracorporeal membrane oxygenation (ECMO) support, and cardiopulmonary resuscitation (CPR).

Clinical parameters including hemodynamics and inotropic equivalents, [26] and laboratory tests including complete blood cell count, liver function, renal function, serum levels of relevant electrolytes, and arterial blood gas were recorded at the three-time points, namely, hospital admission, postoperative stage, and RRT initiation. The BW, presented with the unit of the kilogram, was measured every day by bed weighing scales which were calibrated.

The severity scores including the Glasgow Coma Scale (GCS), the Acute Physiology and Chronic Health Evaluation II (APACHE II) scores [27], the Multiple Organ Dysfunction Score (MODS), [28] the Logistic Organ Dysfunction Score (LODS), [29] and the Sequential Organ Failure Assessment (SOFA) scores [30], were also measured at the postoperative stage and RRT initiation. (S1 Appendix)

Definitions

The perioperative BW change was defined as the percentage change of BW from “hospital admission” to “ICU admission immediately after CS (postoperative stage)” [100% x (BW_{ICU}−BW_{hosp})/ BW_{hosp}]. The postoperative change was the change from “ICU admission” to “RRT initiation” [100% x (BW_{ICU}−BW_{hosp})/ BW_{hosp}]. The pre-RRT change was the change from “hospital admission” to “RRT initiation” [100% x (BW_{RRT}−BW_{hosp})/ BW_{hosp}]. The post-RRT change was the change from “RRT initiation” to “hospital discharge or death” [100% x (BW_{dis}−BW_{RRT})/ BW_{RRT}]. Fluid overload was defined as the presence of both oliguria (urine output < 0.5ml/kg/hr for ≥ 12 hours) and severely impaired oxygenation (PaO2/FiO2 < 200).

Clear consciousness was defined with GCS ≥ 14 points. Estimated glomerular filtration rate (eGFR) was calculated using the Chinese Modification of Diet in Renal Disease equation. [31] Besides, the comorbidities including diabetes mellitus (DM), hypertension, chronic kidney disease (CKD), [32] sepsis, [33] shock, coronary artery disease (CAD), cerebrovascular accident (CVA), chronic obstructive pulmonary disease (COPD) and liver cirrhosis were defined according to previous medical records and/or relevant examinations. Moreover, heart failure was classified according to New York Heart Association functional classification.

The indications for RRT initiation included: (1) blood urea nitrogen (BUN) > 80 mg/dl and serum creatinine (sCr) > 2 mg/dl with uremic symptoms, (2) a central venous pressure level > 12 mmHg or pulmonary edema with a PaO2/FiO2 < 300, (3) serum potassium > 5.5 mmol/l refractory to treatment, (4) urine output < 100 ml/8 hours refractory to diuretics treatment, and (5) a pH < 7.2 in arterial blood gas.

The dialysis modality was chosen according to the hemodynamics of patients. Continuous venovenous hemofiltration (CVVH) was used if the dose of the inotropic equivalent of more than 15 points was required to maintain systolic blood pressure up to 120 mmHg. CVVH was performed with high-flux filters (Hemofilter, PAN-10, Asahi Kasei, Japan) using HF 400 (Infomed, Geneva, Switzerland) and a hemofiltration flow of 35 ml/kg per hour with a blood flow of 200 ml per minute. Replacement fluid was bicarbonate-buffered and was administered preditionally at a dynamically adjusted rate to achieve the desired fluid therapy goals. Default composition was 142 mEq/l Na, 33 mEq/l bicarbonate, 1.4 mEq/l Mg, and 2.6 mEq/l Ca. Hemodialysis was performed using low-flux polysulfone hemofilter (KF-18C, Kawasumi Laboratories, Japan). Conventional intermittent hemodialysis was performed for four hours except for the first and second sessions with a blood flow of 200 ml/min and a dialysate flow of 500 ml/min. Hemodialysis adequacy assessment was measured: KT/V = [(in vitro urea clearance)× (prescribed time)]/predialysis total body water. The urea distribution volume is roughly equal to the total body water. Vascular access was obtained by percutaneous placement of a double-lumen catheter.
Statistical analysis

The statistical analyses were performed using the Scientific Package for Social Science (PASW Statistics for Windows, Version 22.0, Chicago: SPSS Inc) and the R 2.12.1 (R Foundation for Statistical Computing, Vienna, Austria) software. A variable was deleted if the missing data > 5% or was replaced by linear interpolation if the missing data < 5%.

Categorical variables were expressed as “numbers (percentages).” Continuous variables were expressed as “mean ± standard deviation (SD)” for normal distribution and “mean ± SD [median, interquartile range (IQR)]” for non-normal distribution. The chi-square test, or the Fisher’s exact test if the expected value of any box is \( \leq 5 \), was used to analyze categorical variables. The independent t-test for normal distribution or Mann-Whitney U test for non-normal distribution was used to compare continuous variables.

If the perioperative or the pre-RRT BW change was demonstrated to have a significant association with mortality in the independent t-test, the generalized additive model (GAM) was applied to present the change of death risk according to the percentage BW changes and to further determine the cut-point for postoperative mortality. The Kaplan-Meier survival curves with log-rank test were drawn to compare the patient survival between groups categorized by the cut-point determined by GAM.

Subsequently, the clinical variables at patients’ initial admission, perioperative stage, postoperative stage and pre-RRT stage were considered as candidate variables for Cox proportional hazards model. The multivariate Cox proportional hazards model with stepwise selection method was used to evaluate the independent indicators of the 30-day mortality from the variables which showed significances (\( p \leq 0.05 \)) in univariate analysis, and to investigate their regression coefficient, hazard ratio (HR), 95% confidence interval (CI) and p-value.

Finally, the receiver operating characteristic (ROC) curve with an area under the curve (AUC), along with the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) was used to exam the predictive ability for postoperative mortality of the multivariate Cox proportional hazards model. Besides, the GAM was applied again to measure the probability of the death and draw the relationship plots between postoperative mortality and BW changes in the perioperative and postoperative period. In all statistical analyses, a two-sided \( p \leq 0.05 \) was considered statistically significant.

Results

During the enrollment period from January 2001 to January 2014, a total of 924 patients underwent CS and RRT in the ICUs. After excluding 230 patients who undergoing chronic RRT, 61 patients whose RRT were undertaken before the CS, 7 patients with GCS < 14 points at hospital admission, 183 patients received CS > 14 days after hospital admission, and 255 patients received RRT > 7 days after CS, 188 patients (70 female, mean age 63.7 ± 15.2 years) were enrolled. The enrollees were categorized into survivors (n = 124, 66.0%) and non-survivors (n = 64, 34.0%). (Fig 1) In non-survivors, the median duration from CS to death was ten days. With the setting of \( \alpha 0.05 \) and odds ratio (OR) 2.145, the estimated power of logistic regression model in the current study was calculated as 0.98 by using the G-Power. [34].

Clinical characteristics and variables

Compared to the survivors, the non-survivors had a higher proportion of having DM, but a lower proportion of CKD (\( p < 0.001 \)) and lower values of CCI. The non-survivors received fewer units of perioperative packed red blood cells (PRBC) transfusion but had a higher probability of using IABP. They also had a higher probability of a shock as the etiology of AKI.
(p = 0.002) and used CAVH as the majority of RRT modality (p < 0.001). (all p = 0.001 except otherwise expressed) (Table 1)

Besides, the non-survivors had higher eGFR from hospital admission (p = 0.002) to the postoperative stage (p = 0.002) and at RRT initiation (p = 0.001). They also had higher hemoglobin at hospital admission. At both postoperative stage and RRT initiation, the non-survivors had lower blood pressure (BP), serum albumin, and GCS, as well as higher values of some electrolytes and liver biochemistries, higher heart rate (HR) and higher severity scores (the SOFA and the LODS at postoperative stage, along with the APACHE-II, the SOFA, the LODS, and the MODS at RRT initiation). As to the central venous pressure (CVP) levels, the non-survivors had lower CVP levels at postoperative stage (p = 0.032) but higher at RRT initiation (p = 0.013) comparing with the survivors. (Table 2 and S1–S3 Tables)

Body weight change and postoperative outcome

Compared to the survivors, the non-survivors had significantly higher perioperative BW change (3.6 ± 6.1% versus 0.1 ± 8.3%, p = 0.012) and pre-RRT BW change (6.4 ± 8.3 versus 3.6 ± 6.9, p = 0.841). An increase of 1% perioperative BW change was associated with 0.07 folds increase in the 30-day postoperative mortality after adjustment.

However, there were no significant differences between non-survivors and survivors in the perioperative BW change (2.7 ± 6.0% versus 4.2 ± 11.4%, p = 0.335), as well as the proportion of presenting fluid overload at postoperative stage (20.3% versus 33.1%, p = 0.067) and at RRT initiation (32.8% versus 25.8%, p = 0.312). Meanwhile, the period from hospital admission to postoperative stage (4.2 ± 3.5 versus 4.5 ± 3.6 days, p = 0.715), the period from postoperative stage to RRT initiation (1.9 ± 1.4 versus 1.9 ± 1.4 days, p = 0.501), and the period from hospital admission to RRT initiation (6.0 ± 3.8 versus 6.3 ± 4.0 days, p = 0.681) were also not statistically different between the non-survivors and the survivors. (Table 1)

By using the GAM, the estimated probability of death at 30-day started to increase significantly when the perioperative BW change reached a cut-point of 2.0%. (plot not shown) Moreover, we found that the patients with perioperative BW change ≥ 2.0% had significantly higher 30-day postoperative mortality than those with perioperative BW change < 2.0% (mortality rate, 45.9% versus 28.4%, p = 0.013). (Fig 1) Otherwise, the hospital LOS [45.0 ± 53.2 versus 47.5 ± 44.6 days, p = 0.743], the ICU LOS (17.3 ± 23.1 versus 17.2 ± 18.3 days, p = 0.989), the...
| Variable                        | Survivors (n = 124) | Non-Survivors (n = 64) | p-value |
|--------------------------------|---------------------|------------------------|---------|
| **Basic demography**           |                     |                        |         |
| Gender, female                 | 46 (37.1%)          | 24 (37.5%)             | 0.957   |
| Age, years                     | 62.7 ± 15.3 [65.8, 77.0] | 65.7 ± 15.0 [69.0, 64.0] | 0.145*  |
| BMI, kg/m²                     | 23.7 ± 3.8          | 23.0 ± 3.5             | 0.250   |
| Smoking                        | 19 (15.3%)          | 5 (7.8%)               | 0.144   |
| Comorbid disease               |                     |                        |         |
| CAD                            | 37 (29.8%)          | 14 (21.9%)             | 0.245   |
| DM                             | 69 (55.6%)          | 51 (79.7%)             | 0.001   |
| Hypertension                   | 76 (61.3%)          | 37 (57.8%)             | 0.644   |
| Heart failure                  |                     |                        | 0.264   |
| NYHA Fc-I                      | 44 (35.5%)          | 18 (28.1%)             |         |
| NYHA Fc-II                     | 45 (36.3%)          | 33 (51.6%)             |         |
| NYHA Fc-III                    | 22 (17.7%)          | 8 (12.5%)              |         |
| NYHA Fc-IV                     | 2 (1.6%)            | 2 (3.1%)               |         |
| CKD                            | 25 (20.2%)          | 1 (1.6%)               | < 0.001 |
| Severe COPD                    | 3 (2.4%)            | 1 (1.6%)               | 0.700   |
| CVA                            | 5 (4.0%)            | 0 (0.0%)               | 0.103   |
| Cirrhosis of liver             | 3 (2.4%)            | 1 (1.6%)               | 0.700   |
| Charlson Comorbidity Index     | 2.79 ± 2.87 [2, 12] | 1.52 ± 0.69 [2, 4]    | 0.100*  |
| **Categories of surgeries**    |                     |                        | 0.975   |
| Valvar replacement             | 44 (35.5%)          | 22 (34.4%)             |         |
| CABG                           | 43 (34.7%)          | 26 (40.6%)             |         |
| CABG+valvar replacement        | 9 (7.3%)            | 4 (6.4%)               |         |
| Heart transplantation          | 3 (2.4%)            | 1 (1.6%)               |         |
| Endovascular stent grafting    | 9 (7.3%)            | 5 (7.8%)               |         |
| Others                         | 16 (12.9%)          | 6 (9.4%)               |         |
| **Perioperative blood transfusion** |                 |                        |         |
| Whole Blood, IU                | 0.16 ± 0.75 [0, 5]  | 0.21 ± 0.79 [0, 4]     | 0.426*  |
| Packed red blood cells, IU     | 1.57 ± 3.92 [0, 33] | 0.30 ± 1.11 [0, 7]     | 0.002*  |
| Fresh frozen plasma, IU        | 2.77 ± 3.60 [3, 30] | 3.73 ± 3.44 [3, 18]    | 0.017*  |
| Platelet, IU                   | 6.66 ± 7.30 [6, 60] | 8.34 ± 8.24 [6, 42]    | 0.188*  |
| Cryoprecipitate, IU            | 1.01 ± 3.87 [0, 24] | 0.72 ± 2.05 [0, 12]    | 0.238*  |
| **Etiology of AKI**            |                     |                        | 0.957   |
| Shock                          | 104 (83.9%)         | 57 (89.1%)             | 0.002   |
| Sepsis                         | 27 (21.8%)          | 10 (15.6%)             | 0.957   |
| **Modality of RRT**            |                     |                        | <0.001  |
| IHD                            | 29 (23.4%)          | 0 (0.0%)               |         |
| CVVH                           | 5 (4.0%)            | 0 (0.0%)               |         |
| CAVH (with ECMO)               | 47 (37.9%)          | 57 (89.1%)             |         |
| Mixed method                   | 22 (17.7%)          | 5 (7.8%)               |         |
| SLEDD-f / SLEDD                | 21 (16.9%)          | 2 (3.1%)               |         |
| **Other important remarks**    |                     |                        |         |
| Intra-aortic balloon pump      | 10 (8.1%)           | 16 (25.0%)             | 0.001   |
| Cardiopulmonary resuscitation  | 6 (4.8%)            | 0 (0.0%)               | 0.074   |
| Post-op diuretics use          | 78 (62.9%)          | 48 (75.0%)             | 0.095   |
| Duration of CS, hours          | 4.5±2.0 [4.2, 13.3] | 5.1±2.2 [4.5, 12.4]    | 0.084*  |

(Continued)
duration of ventilator support (22.8 ± 49.2 versus 16.5 ± 17.9 days, p = 0.208), and the duration from the CS to RRT initiation (1.6 ± 1.2 versus 2.0 ± 1.5 days, p = 0.064) were noted of significant differences between the groups with perioperative BW change ≥ 2% and < 2%. (Fig 2)

Predictors of 30-day postoperative mortality

Then we evaluated the influences of all the variables including basic characteristics and clinical variables using the univariate Cox proportional hazards model. The variables with p ≤ 0.05 on univariate analysis were put into the multivariate model for further analysis. These selected variables for multivariate analysis included DM, CKD, and some laboratory tests [hemoglobin, eGFR, GOT, and bilirubin (Bil-T)] at hospital admission; the clinical variables [HR, mean arterial pressure (MAP), CVP, IABP, perioperative PRBC and FFP transfusion, perioperative BW change and BW change after RRT], the laboratory tests (WBC, eGFR, sodium, glutamic oxaloacetic transaminase (GOT), Bil-T, albumin, lactate, PaO2), and the severity scores (GCS, SOFA Score and LODS) at postoperative stage; as well as the clinical variables (shock as etiology of AKI, modality with CAVH of RRT, HR, MAP, CVP, IE score), the laboratory tests (platelet, eGFR, sodium, calcium, GOT, albumin, Bil-T, lactate) and the severity scores (GCS, APACHE-II, SOFA Score, LODS and MODS) at RRT initiation. Also, a propensity score composed of age, body mass index, gender, CCI, eGFR, as well as the days between hospital admission to surgery, was applied for the baseline difference adjustment in the multivariate Cox proportional hazards model.

The multivariate Cox proportional hazards model subsequently disclosed several independent predictors of 30-day postoperative mortality. These independent predictors included perioperative BW change (HR 1.07, 95% CI 1.03–1.12, p = 0.001), Post-RRT BW change (HR

Table 1. (Continued)

| Variable                        | Survivors (n = 124) | Non-Survivors (n = 64) | p-value |
|---------------------------------|---------------------|------------------------|---------|
| Hospital to ICU, day            | 4.5 ± 3.6 [3, 13]   | 4.2 ± 3.5 [3, 13]      | 0.715*  |
| ICU to RRT, day                 | 1.9 ± 1.4 [1, 6]    | 1.9 ± 1.4 [1, 5]       | 0.501*  |
| Hospital to RRT, day            | 6.3 ± 4.0 [4, 5]    | 6.0 ± 3.8 [4, 5]       | 0.681*  |
| Peri-op BW change, %            | 0.1 ± 8.3 [0.0, 65.0] | 3.6 ± 6.1 [0.6, 24.2]  | 0.012*  |
| Post-op BW change, %            | 4.2 ± 11.4 [2.3, 44.4] | 2.7 ± 6.0 [4.0, 38.2]  | 0.335*  |
| Pre-RRT BW change, %            | 3.6 ± 6.9 [0.0, 104.8] | 6.4 ± 8.3 [0.4, 29.7]  | 0.841*  |
| Post-RRT BW change, %           | -10.2 ±14.6 [-8.3, 67.7] | 0.7 ±10.2 [0.4, 52.3]  | <0.001* |
| Fluid overload at ICU (post-op stage)** | 44 (33.1%) | 13 (20.3%) | 0.067   |
| Fluid overload at RRT initiation*** | 32 (25.8%) | 21 (32.8%) | 0.312   |

Note: Categorical variables were expressed as numbers (percentages) and analyzed using Chi-square test, or Fisher’s exact test if the expected value of any box is ≤5.

Continuous variables with normal distribution were expressed as “mean ± standard deviation” and analyzed using independent t-test.

*Continuous variables with non-normal distribution were expressed as “mean ± standard deviation [median, interquartile range]” and compared using Mann-Whitney U test.

** Fluid overload was defined as the presence of both oliguria (urine output <0.5ml/kg/h for ≥12 hrs) and severely impaired oxygenation (PaO2/FiO2<200).

Abbreviations: AKI, acute kidney injury; BMI, body mass index; CAGB, coronary artery bypass grafting; CAD, coronary artery disease; CAVH, continuous arteriovenous hemofiltration; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CS, cardiac surgery; CVA, cerebrovascular accident; CS, cardiac surgery; CVVH, continuous venovenous hemofiltration; DM, diabetes mellitus; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IHD, intermittent hemodialysis; NYHA Fc, New York Heart Association functional classification; Peri-op, perioperative; Post-op, postoperative; PRBC, packed red blood cells; RRT, renal replacement therapy; SLEDD, slow extended daily dialysis; SLEDD-f, sustained low-efficiency daily dialfiltration

https://doi.org/10.1371/journal.pone.0187280.001
Table 2. Laboratory and clinical variables with statistical differences between survivors and non-survivors.

| Variable                  | Survivors         | Non-Survivors     | p-value |
|---------------------------|-------------------|-------------------|---------|
| At hospital admission     |                   |                   |         |
| **Laboratory tests**      |                   |                   |         |
| Hemoglobin, g/dL          | 11.4 ± 2.5 [11.2, 14.5] | 12.2 ± 2.6 [12.2, 12.5] | 0.020*  |
| Hematocrit, %             | 34.6 ± 7.6 [33.4, 44.1] | 37.1 ± 7.6 [36.3, 35.4] | 0.023*  |
| BUN, mg/dL                | 46.7 ± 29.5 [41.2, 118.7] | 34.4 ± 34.4 [27.2, 89.7] | 0.010*  |
| Creatinine, mg/dL         | 3.4 ± 6.1 [2.1, 65.4] | 1.9 ± 1.4 [1.4, 7.4] | 0.002*  |
| eGFR, ml/min/1.73m²       | 39.5 ± 29.5 [33.4, 145.6] | 51.5 ± 27.7 [50.2, 130.4] | 0.002*  |
| GOT, IU/L                 | 56.9 ± 120.8 [26.0, 1153.0] | 155.9 ± 665.5 [34.0, 5318.0] | 0.002*  |
| Bil-T, mg/dL              | 1.1 ± 1.1 [0.7, 8.1] | 1.4 ± 1.3 [1.0, 7.2] | 0.008*  |
| At ICU admission (postoperative stage) |                   |                   |         |
| **Hemodynamics and vital signs** |                   |                   |         |
| HR, /min                  | 98.5 ± 21.2       | 106.6 ± 20.1      | 0.012   |
| SBP, mmHg                 | 125.2 ± 32.2      | 108.7 ± 26.6      | 0.001   |
| MAP, mmHg                 | 84.3 ± 19.6       | 75.2 ± 16.9       | 0.002   |
| CVP, mmHg                 | 12.0 ± 5.3        | 10.4 ± 4.9        | 0.039   |
| **Laboratory tests**      |                   |                   |         |
| WBC, 10^3/uL              | 13.7± 4.8 [11.4, 26.0] | 10.5 ± 5.8[1.0, 3.0] | 0.020*  |
| BUN, mg/dL                | 40.4 ± 21.4 [36.4, 118.2] | 33.3 ± 21.2 [28.1, 109.9] | 0.007*  |
| SCr, mg/dL                | 3.3 ± 5.1 [2.4, 55.6] | 2.1 ± 1.3 [1.7, 7.2] | 0.003*  |
| eGFR, ml/min/1.73m²       | 32.9 ± 24.6 [26.1, 146.1] | 39.4 ± 16.1 [41.2, 101.6] | 0.002*  |
| Albumin, g/dL             | 3.4 ± 0.6         | 3.0 ± 0.7         | 0.004   |
| Sodium, mEq/L             | 139.0± 7.3 [139.0, 32.0] | 144.2 ± 7.8 [143.0, 48.0] | <0.001* |
| GOT, IU/L                 | 120.5 ± 155.7 [66.5, 1210.0] | 318.2 ± 442.0 [167.5, 2084.0] | <0.001* |
| Bil-T, mg/dL              | 2.9 ± 9.4 [1.3, 102.0] | 2.9 ± 2.6 [2.0, 14.0] | <0.001* |
| Lactate, mEq/L            | 6.4 ± 5.7 [4.7, 24.6] | 9.1 ± 6.5 [6.95, 23.8] | 0.002*  |
| PaO2, mmHg                | 140.8 ± 79.8 [113.5, 427.5] | 167.5 ± 87.0 [133.4, 346.3] | 0.017*  |
| **Severity scores**       |                   |                   |         |
| GCS, points               | 13.1 ± 4.1 [15, 12] | 10.3 ± 5.2 [15, 12] | <0.001* |
| SOFA Score, points        | 9.0 ± 3.2 [9, 15] | 11.1 ± 3.2 [11, 15] | <0.001* |
| LODS, points              | 14.2 ± 3.4 [15, 12] | 16.5 ± 1.2 [17, 5] | <0.001* |
| At RRT initiation         |                   |                   |         |
| **Hemodynamics and vital signs** |                   |                   |         |
| HR, /min                  | 99.1 ± 20.2       | 109.1 ± 21.1      | 0.002   |
| SBP, mmHg                 | 123.5 ± 27.4      | 105.8 ± 24.9      | <0.001  |
| MAP, mmHg                 | 83.3 ± 16.2       | 76.3 ± 16.2       | <0.001  |
| CVP, mmHg                 | 12.3 ± 5.1 [12, 25] | 14.1 ± 5.4 [13, 31] | 0.013*  |
| IE, mcg/kg/min            | 34.8 ± 243.5 [6.7, 2719.4] | 25.2 ± 24.3 [19.1, 168.2] | <0.001* |
| **Laboratory tests**      |                   |                   |         |
| Platelet, 10^3/uL         | 133.3 ± 62.3 [129.5, 344.0] | 108.4 ± 64.6 [94.5, 350.0] | 0.004*  |
| BUN, mg/dL                | 54.0 ± 29.0 [49.9, 156.7] | 45.1 ± 24.8 [36.9, 99.4] | 0.029*  |
| SCr, mg/dL                | 4.3 ± 6.7 [3.2, 73.4] | 2.7 ± 1.6 [2.1, 7.0] | <0.001* |
| eGFR, ml/min/1.73m²       | 24.0 ± 17.3 [19.3, 90.8] | 30.4 ± 14.6 [29.6, 61.0] | 0.001*  |
| Albumin, g/dL             | 3.3 ± 0.6         | 3.0 ± 0.7         | 0.017   |
| Sodium, mEq/L             | 140.3 ± 6.6 [139.3, 36.2] | 145.9 ± 7.5 [145.0, 37.0] | <0.001* |

(Continued)
1.06, 95% CI 1.04–1.08, p < 0.001), perioperative PRBC transfusion (HR 0.65, 95% CI 0.51–0.82, p < 0.001), Modality with CAVH (HR 4.09, 95% CI 1.85–9.05, p = 0.001), HR at RRT (HR 1.02, 95% CI 1.01–1.03, p = 0.001), SOFA score at RRT (HR 1.22, 95% CI 1.13–1.33, p<0.001). (Table 3 and S4 Table) The predictive ability for the postoperative mortality of the perioperative BW change persisted when taking the situation of fluid overload at the postoperative stage and RRT initiation for adjustment. (HR 1.045, 95% CI 1.004–1.088, p = 0.032; and HR 1.046, 95% CI 1.006–1.088, p = 0.023, respectively).

From the plot drawn using the GAM with adjustment to all other independent predictors mentioned above, we found that the probability of postoperative mortality significantly raised when perioperative BW change arrived 2.0% and progressed until the peak at perioperative BW change of 15.0%. (Fig 3)

Finally, the predictability of the current multivariate Cox proportional hazards model for postoperative mortality was proved to be excellent by the ROC analysis. (AUC 0.925, 95% CI 0.877–0.958, p<0.001, sensitivity 0.94; specificity 0.77, PPV 0.67, NPV 0.96).

Discussions

Since CS-associated AKI is different from septic AKI in pathophysiologic mechanisms and patient prognoses, we used relatively strict inclusion criteria to minimize the influence of other confounding factors such as sepsis and to conduct a “relatively pure” cohort of CS patients with severe postoperative AKI. In a recently published single-center matched cohort study evaluating long-term outcomes for CS patients with dialysis-requiring AKI, the independent risk factors associated with elevated all-cause mortality were demonstrated to be increased age, with history of congestive heart failure, lower preoperative SCr, longer interval between CS
and RRT initiation, and the need for mechanical ventilation or an intra-aortic balloon pump at RRT initiation. [19] Because of the different “time limits from CS to RRT initiation” in the inclusion criteria of the study by Thongprayoon et al. [19] (≦ 30 days) and the current study (≦ seven days), the study populations were different between the two studies. Furthermore, Thongprayoon et al. [19] did not take the variables about BW changes into consideration as risk factors.

To the best of our knowledge, the current prospective multicenter cohort study is the first investigation to evaluate the association between perioperative BW change and postoperative 30-day mortality in CS patients with RRT-requiring postoperative AKI. The 30-day mortality rate of CS patients with severe postoperative AKI requiring RRT in our study was 34.0%, which was comparable with the 32.5% of the CS patients with AKI (including mild form AKI) in the previous study. [35]

Body weight change and patient outcomes

In the selected population, the risk of postoperative mortality significantly raised when the perioperative BW change arrived 2.0%. A BW gain of ≥ 2% carries a twofold probability of 30-day mortality than those whose BW gain < 2%. Even after adjustment for baseline differences using propensity score, and with fluid overload at either postoperative stage or RRT initiation, the perioperative BW change in continuous form was proved as an independent indicator for 30-day mortality.

BW change is a useful marker for fluid storage outside the circulatory space, [36] and is a good indicator evaluating the progression of the nutritional status. [10] In the population of heart failure, BW gain ≥ 0.91 kg over three days was a significant indicator for heart function...
decompensation, while a BW loss $\geq 6\%$ at any time during follow-up was a strong predictor of worse 8-months survival. Similarly, a BW loss $>5\%$ during follow-up within a 6-month period is a significant risk factor for death and CV death in patients post myocardial infarction. As for the CS patients, a BW loss $\geq 10\%$ in the six months before the admission was an association with a prolonged hospital LOS.

In the current study, we found that the postoperative mortality was raised when the perioperative BW change increased to 2–15% (estimated 1.2–9 kg in a 60-kg adult) during a period with a mean value of 4.4 days and a median value of 3 days. Comparing with these previous studies, we demonstrated that the patient survival could be affected by a smaller BW change within a shorter observation period. Moreover, the scale of BW change in the current study was comparable with the findings in studies mentioned above when taking the length of follow-up period into consideration.

Fluid status changes and patient outcomes

When discussing the BW change, fluid balance should be taken into consideration. Among critically ill patients with AKI, a fluid accumulation of $>10\%$ BW was associated with a higher 30-days, 60-days, and in-hospital mortality in the western population. Similar findings could also be seen in the Asian population. A multicenter prospective study conducted by Wang et al. found that the fluid accumulation of $>10\%$ BW within the first three days of ICU admission was an independent risk factor for the occurrence of AKI and the

Table 3. Independent predictors of 30-day postoperative mortality using multivariate Cox proportional hazards model.

| Predictor                              | B    | SE   | HR   | 95% CI         | p-value |
|----------------------------------------|------|------|------|----------------|---------|
| Peri-op BW change $^a$                 | 0.07 | 0.02 | 1.07 | 1.03–1.12      | 0.001   |
| Post-RRT BW change $^a$                | 0.06 | 0.01 | 1.06 | 1.04–1.08      | <0.001  |
| Peri-op PRBC transfusion $^a$          | -0.44| 0.12 | 0.65 | 0.51–0.82      | <0.001  |
| CAVH (with ECMO) $^b$                  | 1.41 | 0.41 | 4.09 | 1.85–9.05      | 0.001   |
| HR at RRT $^a$                         | 0.02 | 0.01 | 1.02 | 1.01–1.03      | 0.001   |
| MAP at RRT $^a$                        | -0.02| 0.01 | 0.98 | 0.97–1.00      | 0.024   |
| SOFA Score at RRT $^a$                 | 0.20 | 0.04 | 1.22 | 1.13–1.33      | <0.001  |

Notes: Variables were selected to put into multivariate analysis if they had a p $\leq 0.05$ on univariate analysis. These selected variables for multivariate analysis included DM, CKD, and some laboratory tests (hemoglobin, eGFR, GOT, and Bil-T) at hospital admission; the clinical variables (HR, MAP, CVP, IABP, perioperative PRBC and FFP transfusion, perioperative BW change and BW change after RRT), the laboratory tests (WBC, eGFR, sodium, GOT, Bil-T, albumin, lactate, PaO2), and the severity scores (GCS, SOFA Score and LODS) at postoperative stage; as well as the clinical variables [shock as etiology of AKI, CAVH (with ECMO), HR, MAP, CVP, IE], the laboratory tests (platelet, eGFR, sodium, calcium, GOT, albumin, Bil-T, lactate) and the severity scores (GCS, APACHE-II, SOFA Score, LODS and MODS) at RRT initiation. Also, a propensity score composed of age, body mass index, gender, CCI, eGFR, as well as the days between hospital admission to surgery, was applied for the baseline difference adjustment in the multivariate Cox proportional hazards model.

Duration for analysis is measured using calendar days from cardiac surgery to mortality.

$^a$ every increment of 1 unit or point

$^b$ with versus without; “at RRT” denotes “at the timing of RRT initiation.”

Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; B, beta coefficient; Bil-T, total bilirubin; BW, body weight; CAVH, continuous arteriovenous hemofiltration; CCI, Charlson Comorbidity Index; CI, confidence interval; CKD, chronic kidney disease; CVP, central venous pressure; DM, diabetes mellitus; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; FFP, fresh frozen plasma; GCS, Glasgow Coma Scale; GOT, glutamate oxaloacetate transaminase; HR, heart rate; HR, hazard ratio; IABP, intra-aortic balloon pump; IE, inotropic equivalent; LODS, Logistic Organ Dysfunction Score; MAP, mean arterial pressure; MODS, Multiple Organ Dysfunction Score; PaO2, partial arterial pressure of oxygen; Peri-op, perioperative; Post-op, postoperative; PRBC, packed red blood cell; RRT, renal replacement therapy; SE, standard error; SOFA, Sequential Organ Failure Assessment; WBC, white blood cell
increased severity of AKI. In these critically ill patients with AKI, the mean fluid balance within the first three days was 1.4 liters, which was higher in the non-survivors than in the survivors (2.77 versus 0.93 liters, \( p < 0.001 \)). Moreover, the cumulative fluid amount in the first three days was an independent predictor of 28-day mortality. [18] Furthermore, a meta-analysis enrolling 5095 patients from 12 cohort studies confirmed that fluid status, regarding either predefined “fluid overload” (categorical variables) or mean fluid balance (continuous variables), was positively associated with mortality in patients with AKI. [17]

As for the patients received CS, an accumulated fluid balance > 6.5 ml/kg BW (estimated 390 ml in a 60-kg adult) within the first 72 hrs postoperatively was associated with a longer LOS in those with oliguria, [40] and a fluid accumulation of \( \geq 10\% \) BW after CS during the ICU stay was associated with a higher mortality and a longer ICU LOS. [41] Whereas in the CS patients with RRT-requiring AKI, the non-survivors had significant higher fluid accumulation before RRT (8.8% versus 6.1%), after RRT (6.9% versus -0.5%), and during the whole ICU stay (18.0% versus 7.5%) than the survivors. Moreover, a fluid accumulation \( \geq 7.2\% \) during whole ICU stay is demonstrated as the cut-point for 90-day mortality. [42]

These three investigations in postoperative CS population [40–42] evaluated the fluid balance during the ICU stay, in which the period before and during the CS was not specified. While the current study evaluated the BW change at different period section including the preoperative, the perioperative, and the postoperative stages. Moreover, we found the perioperative BW change, which overwhelmed the BW changes at other period sections, showed a significant predictive value of mortality. Besides, the magnitude of the BW change in our study is significantly smaller than the fluid balance in other studies. The existence of the insensible fluid losses which vary depending on the environment and the disease process, [43] and the lean body weight loss secondary to the high catabolic status should take the main responsibility for the gap.
The current study echoed the concept that more intraoperative or perioperative fluid accumulation is associated with adverse postoperative prognoses, [44] and provided a simple and useful BW measurement to predict patient outcomes.

Limitations

Several limitations of this study should be addressed. First, as an observational study, it is subject to bias. Second, current study enrolled a selected population of CS patients with RRT-requiring postoperative AKI. Thus the results may not serve as a representative sample of the all postoperative AKI patients, or AKI patients without RRT, throughout the world. Third, there is no optimal indicator to quantify the change of nutritional status, and the change of BW which is related to catabolic status, during the perioperative stage.

Conclusions

Perioperative BW change was independently associated with an increased risk for 30-day postoperative mortality in CS patients with RRT-requiring AKI. These findings underscore the need for further studies using more optimal indicators to differentiate the effects of nutritional change and fluid retention.

Supporting information

S1 Appendix. Dataset of perioperative body weight change and outcomes.
(XLSX)

S1 Table. Complete clinical variables at hospital admission of the two groups.
(DOC)

S2 Table. Complete clinical variables at ICU admission of the two groups.
(DOC)

S3 Table. Complete clinical variables at renal replacement therapy initiation of the two groups.
(DOC)

S4 Table. Complete multivariate model for predicting 30-day mortality after the operation.
(DOC)

Acknowledgments

This study was financially supported by The Ta-Tung Kidney Foundation, Taiwan National Science Council (grant NSC 96-2314-B-002-164, NSC 96-2314-B-002-033-MY3, NSC 97-2314-B-002-155-MY2, NSC 98-2314-B-002-155-MY4), 101-2314-B-002-085-MY3, 102-2314-B-002-140-MY2, 104-2314-B-002-125-MY3), NTUH (105-FTN20, 106-P02, UN106-014, 106-S3582, 106-P05, VN105-04, 105-S3061, VN104-07, 104-S2718, and NTUH 098–001177, NTUH 100–001667. This study was also supported by the Ministry of Science and Technology (MOST) of the Re-public of China (Taiwan) (grant number, MOST 106-2321-B-182-002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

The authors thank Melanie Yu for the professional English-editing and also express their sincere gratitude to all staff of the Taiwan Clinical Trial Consortium, TCTC.
The members of the National Taiwan University Hospital Study Group on Acute Renal Failure (NSARF) include Kwan-Dun Wu, Tzong-Shinn Chu, Vin-Cent Wu, Chih-Chung Shiao, Chun-Te Huang, Che-Hsiung Wu, Chih-Hsien Wang, I-Jung Tsai, Jian-Jhong Wang, Jui-Hsiang Lin, Li-Jung Tseng, Tai-Shuan Lai, Tao-Min Huang, Ya-Fei Yang, Yu-Feng Lin and Yu-Chang Yeh.

Author Contributions

Conceptualization: Chih-Chung Shiao, Ya-Ting Huang, Tzong-Shinn Chu, Kwan-Dun Wu, Vin-Cent Wu.

Data curation: Tai-Shuan Lai, Tao-Min Huang, Jian-Jhong Wang, Chun-Te Huang, Pei-Chen Wu, Che-Hsiung Wu, I-Jung Tsai, Li-Jung Tseng, Vin-Cent Wu.

Formal analysis: Chih-Chung Shiao, Ya-Ting Huang.

Funding acquisition: Tzong-Shinn Chu, Kwan-Dun Wu, Vin-Cent Wu.

Investigation: Chih-Chung Shiao, Ya-Ting Huang, Vin-Cent Wu.

Methodology: Chih-Chung Shiao, Ya-Ting Huang, Vin-Cent Wu.

Project administration: Tzong-Shinn Chu, Kwan-Dun Wu, Vin-Cent Wu.

Resources: Tai-Shuan Lai, Tao-Min Huang, Jian-Jhong Wang, Chun-Te Huang, Pei-Chen Wu, Che-Hsiung Wu, I-Jung Tsai, Li-Jung Tseng.

Software: Chih-Chung Shiao, Ya-Ting Huang.

Supervision: Chih-Hsien Wang, Tzong-Shinn Chu, Kwan-Dun Wu, Vin-Cent Wu.

Validation: Chih-Hsien Wang, Tzong-Shinn Chu, Kwan-Dun Wu, Vin-Cent Wu.

Visualization: Chih-Chung Shiao, Ya-Ting Huang, Chih-Hsien Wang.

Writing – original draft: Chih-Chung Shiao, Ya-Ting Huang.

Writing – review & editing: Chih-Chung Shiao, Ya-Ting Huang, Chih-Hsien Wang, Tzong-Shinn Chu, Kwan-Dun Wu, Vin-Cent Wu.

References

1. Rosner MH, Okusa MD. Acute Kidney Injury Associated with Cardiac Surgery. Clinical Journal of the American Society of Nephrology. 2006; 1(1):19–32. https://doi.org/10.2215/CJN.002409S5 PMID: 17699187

2. Goren O, Matot I. Perioperative acute kidney injury. British journal of anaesthesia. 2015; 115 Suppl 2: ii3–ii14. Epub 2015/12/15. https://doi.org/10.1093/bja/aev380 PMID: 26658199.

3. Thiele RH, Isbell JM, Rosner MH. AKI associated with cardiac surgery. Clin J Am Soc Nephrol. 2015; 10(3):500–14. Epub 2014/11/08. https://doi.org/10.2215/CJN.07830814 PMID: 25376763; PubMed Central PMCID: PMC4348689.

4. Hobson CE, Yavas S, Segal MS, Schold JD, Trumble CG, Layon AJ, et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation. 2009; 119(18):244–53. Epub 2009/04/29. https://doi.org/10.1161/CIRCULATIONAHA.108.800011 PMID: 19398670.

5. Brown JR, Kramer RS, Coca SG, Panikh CR. Duration of acute kidney injury impacts long-term survival after cardiac surgery. The Annals of thoracic surgery. 2010; 90(4):1142–8. Epub 2010/09/28. https://doi.org/10.1016/j.athoracsur.2010.04.038 PMID: 20866804; PubMed Central PMCID: PMC319730.

6. Olivo JJ, Olivo JJ, Nguyen PT, Kagan A. Acute kidney injury after cardiovascular surgery: an overview. Methodist DeBakey cardiovascular journal. 2012; 8(3):31–6. Epub 2012/12/12. PMID: 23227284; PubMed Central PMCID: PMCPmc3487575.

7. Bellomo R, Auricemma S, Fabbri A, D’Onofrio A, Katz N, McCullough PA, et al. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Int J Artif Organs. 2008; 31(2):166–78. Epub 2008/03/04. PMID: 18311733.
8. Rady MY, Ryan T, Starr NJ. Perioperative determinants of morbidity and mortality in elderly patients undergoing cardiac surgery. Crit Care Med. 1998; 26(2):225–35. Epub 1998/02/19. PMID: 9468158.

9. van Venrooij LM, de Vos R, Borgmeijer-Hoelen MM, Haaring C, de Mol BA. Preoperative unintended weight loss and low body mass index in relation to complications and length of stay after cardiac surgery. The American journal of clinical nutrition. 2008; 87(6):1656–61. Epub 2008/06/11. PMID: 18541553.

10. Reider L, Hawkes W, Hebel JR, D’Adamo C, Magaziner J, Miller R, et al. The association between body mass index, weight loss and physical function in the year following a hip fracture. The journal of nutrition, health & aging. 2013; 17(1):91–5. https://doi.org/10.1007/s12603-012-0073-5 PMID: 23299386; PubMed Central PMCID: PMC3569623.

11. Luchs H, Allison SP, Meier R, Pirlich M, Schneider S, et al. Introductory to the ESPEN Guidelines on Enteral Nutrition: Terminology, definitions and general topics. Clin Nutr. 2006; 25(2):180–6. Epub 2006/05/16. https://doi.org/10.1016/j.clinnu.2006.02.007 PMID: 16697086.

12. Lopez-Jimenez F, Wu CO, Tian X, O’Connor C, Rich MW, Burg MM, et al. Weight change after myocardial infarction—the Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) experience. American heart journal. 2008; 155(3):478–84. https://doi.org/10.1016/j.ahj.2007.10.026 PMID: 18294480; PubMed Central PMCID: PMC2753221.

13. Maisel AS, Shah KS, Barnard D, Jaski B, Frivold G, Marais J, et al. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial. Journal of cardiac failure. 2016; 22(4):283–93. Epub 2015/10/04. https://doi.org/10.1016/j.cardfail.2015.09.014 PMID: 26433086.

14. Van den Broeck J. Malnutrition and mortality. Journal of the Royal Society of Medicine. 1995; 88 (9):487–90. PMID: 7562842; PubMed Central PMCID: PMC1295323.

15. Varadhan KK, Lobn DN, Jungvqvist O. Enhanced recovery after surgery: the future of improving surgical care. Crit Care Clin. 2010; 26(3):527–47. x. https://doi.org/10.1016/j.ccc.2010.04.003 PMID: 20643305.

16. Bass BH, Disney ME, Morrison-Smith J. Effect of salbutamol on respiratory function in children with asthma. Lancet. 1969; 2(7617):438. Epub 1969/08/23. PMID: 4184517.

17. Zhang L, Chen Z, Diao Y, Yang Y, Fu P. Associations of fluid overload with mortality and kidney recovery in patients with acute kidney injury: A systematic review and meta-analysis. Journal of critical care. 2015; 30(4):860 e7–13. Epub 2015/05/17. https://doi.org/10.1016/j.jcc.2015.03.025 PMID: 25979272.

18. Wang N, Jiang L, Zhu B, Wen Y, Xi XM. Fluid balance and mortality in critically ill patients with acute kidney injury: a multicenter prospective epidemiological study. Crit Care. 2015; 19:371. Epub 2015/10/27. https://doi.org/10.1186/s13054-015-1085-4 PMID: 26494153; PubMed Central PMCID: PMC4619072.

19. Thongprayoon C, Cheungpasitporn W, Shah IK, Kashyap R, Park SJ, Kashani K, et al. Long-term Outcomes and Prognostic Factors for Patients Requiring Renal Replacement Therapy After Cardiac Surgery. Mayo Clin Proc. 2015; 90(7):857–64. https://doi.org/10.1016/j.mayocp.2015.03.026 PMID: 26141328.

20. Shiao CC, Wu VC, Li WY, Lin YF, Hu FC, Young GH, et al. Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery. Crit Care. 2009; 13(5):R171. PubMed https://doi.org/10.1186/cc8147 PMID: 19875654.

21. Lin YF, Ko WJ, Wu VC, Chen YS, Chen YM, Hu FC, et al. A modified sequential organ failure assessment score to predict hospital mortality of postoperative acute renal failure patients requiring renal replacement therapy. Blood purification. 2008; 26(6):547–54. PubMed https://doi.org/10.1159/000178771 PMID: 19052448.

22. Wu VC, Ko WJ, Chang HW, Chen YW, Lin YF, Shiao CC, et al. Risk factors of early dialysis after weaning from postoperative acute renal replacement therapy. Intensive Care Med. 2008; 34(1):101–8. PubMed https://doi.org/10.1007/s00134-007-0813-x PMID: 17701162.

23. Krupski WC, Neher MR, Whitehill TA, Lawson RC, Streeker PK, Hiatt WR. Negative impact of cardiac evaluation before vascular surgery. Vascular medicine (London, England). 2000; 5(1):3–9. Epub 2000/03/29. PubMed https://doi.org/10.1177/135886360000500102 PMID: 10737150.

24. Kim WH, Park JY, Ok S-H, Shin I-W, Sohn J-T. Association Between the Neutrophil/Lymphocyte Ratio and Acute Kidney Injury After Cardiovascular Surgery: A Retrospective Observational Study. Medicine. 2015; 94(43):e1867. https://doi.org/10.1097/MD.000000000001867 00005792-201510270-00053. PMID: 26512598.

25. Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Annals of surgery. 2005; 242(3):326–41; discussion 41–3. Epub 2005/09/02. PubMed https://doi.org/10.1097/01.sla. 0000179621.33268.83 PMID: 16135919; PubMed Central PMCID: PMCPmc1357741.
26. Chen YS, Ko WJ, Lin FY, Huang SC, Chou TF, Chou NK, et al. Preliminary result of an algorithm to select proper ventricular assist devices for high-risk patients with extracorporeal membrane oxygenation support. J Heart Lung Transplant. 2001; 20(8):850–7. PMID: 11502407.

27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical care medicine. 1985; 13(10):818–29. PMID: 3928249.

28. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995; 23(10):1638–52. Epub 1995/10/01. PMID: 7587228.

29. Heldwein MB, Badreldin AM, Doerr F, Lehmann T, Bayer O, Doenst T, et al. Logistic Organ Dysfunction Score (LODS): a reliable postoperative risk management score also in cardiac surgical patients. Journal of cardiothoracic surgery. 2011; 6:110. Epub 2011/09/20. https://doi.org/10.1186/1749-8090-6-110 PMID: 21923900; PubMed Central PMCID: PMCPmc3184266.

30. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive care medicine. 1996; 22(7):707–10. PMID: 8844239.

31. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17(10):2937–44. PubMed https://doi.org/10.1681/ASN.2006040368 PMID: 16988059.

32. Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006; 42(1):66–72. PubMed https://doi.org/10.1086/498509 PMID: 16323094.

33. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study. Lancet. 2003; 361(9363):1077–83. Epub 2003/04/04. https://doi.org/10.1016/S0140-6736(03)12892-9 PMID: 12672310.

34. Stein A, de Souza LV, Belettti CR, Menegazzo WR, Viégas Jú R, Costa Pereira EM, et al. Fluid overload and changes in serum creatinine after cardiac surgery: predictors of mortality and longer intensive care stay. A prospective cohort study. Crit Care. 2012; 16(3):R99. https://doi.org/10.1186/cc11368 PMID: 22651844; PubMed Central PMCID: PMCPmc3580649.

35. Godin M, Bouchard J, Mehta RL. Fluid balance in patients with acute kidney injury: emerging concepts. Nephron Clin Pract. 2013; 123(3–4):238–45. Epub 2013/09/07. https://doi.org/10.1159/000345713 PMID: 24008395.

36. Bouchard J, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009; 76(4):422–7. https://doi.org/10.1038/ki.2009.159 PMID: 19436332.

37. Chau K, Schisler T, Er L, Jaswal D, Cheung C, Israel A, et al. Fluid balance, change in serum creatinine and urine output as markers of acute kidney injury post cardiac surgery: an observational study. Canadian journal of kidney health and disease. 2014; 1:19. Epub 2014/01/01. https://doi.org/10.1186/s40697-014-0019-4 PMID: 25960885; PubMed Central PMCID: PMC4424577.

38. Xu J, Shen B, Fang Y, Liu Z, Zou J, Liu L, et al. Postoperative Fluid Overload is a Useful Predictor of the Short-Term Outcome of Renal Replacement Therapy for Acute Kidney Injury After Cardiac Surgery. Medicine. 2015; 94(33):e3160. https://doi.org/10.1097/MD.0000000000001360 PMID: 26287422; PubMed Central PMCID: PMC4616450.
43. El-Sharkawy AM, Sahota O, Maughan RJ, Lobo DN. The pathophysiology of fluid and electrolyte balance in the older adult surgical patient. Clin Nutr. 2014; 33(1):6–13. Epub 2013/12/07. https://doi.org/10.1016/j.clnu.2013.11.010 PMID: 24308897.

44. Varadhan KK, Lobo DN. A meta-analysis of randomised controlled trials of intravenous fluid therapy in major elective open abdominal surgery: getting the balance right. The Proceedings of the Nutrition Society. 2010; 69(4):488–98. https://doi.org/10.1017/S0029665110001734 PMID: 20515521.